Anti-PD-(L)1 for KRAS-mutant advanced non-small-cell lung cancers: a meta-analysis of randomized-controlled trials.

Thierry LandreGregoire JusteauJean-Baptiste AssiéKader ChouahniaClaire DavoineChérifa TalebChristos ChouaïdBoris Duchemann

Published in: Cancer immunology, immunotherapy : CII (2021)

Anti-PD-(L)1 with or without chemotherapy seemed to achieve longer OS and PFS than chemotherapy alone for patients with KRAS-mutant and wild-type KRAS advanced NSCLCs, with an even greater OS benefit for the former.

Keyphrases

wild type
locally advanced
systematic review
single cell
radiation therapy
rectal cancer
stem cells
chemotherapy induced
childhood cancer